• Cycloastragenol in Glucocorticoid-Induced Osteonecrosis

  2026-08-24

  A 2024 in vivo study found that cycloastragenol reduced femoral-head necrosis, trabecular bone loss, and osteoclast-associated molecular changes in a methylprednisolone-induced rat model of GIONFH. By integrating micro-CT, angiography, histology, qPCR, and Western blotting, the work identifies osteoclast suppression as a measurable hip-preservation strategy while leaving important translational questions unresolved.

• MK-5108 (VX-689): Reliable Cell Assays

  2026-08-23

  This scenario-based guide explains how MK-5108 (VX-689), SKU A4120, can support interpretable Aurora-A perturbation studies in cell viability, proliferation, and cytotoxicity workflows. It covers assay design, DMSO formulation, dose interpretation, and practical criteria for selecting a reliable research reagent.

• PAD4-IN-2 TFA: Tumor-Targeted Workflows

  2026-08-22

  PAD4-IN-2 TFA connects tumor-directed uptake with inhibition of the PAD4–H3cit–NET axis, making it useful for studying cancer-cell migration, neutrophil biology, and immune remodeling in one workflow. This guide translates the Compound 5i TFA evidence base into practical assay design, controls, and troubleshooting decisions.

• Deuterium-Labeled Degarelix: Efficient Synthesis

  2026-08-22

  The reference study reports a 13-step, 14% overall synthesis of deuterium-labeled degarelix acetate, using D2O/D3PO4 to introduce a d7-naphthyl label into an amino-acid precursor. Its main contribution is a practical route to a stable-isotope internal standard for future absorption, distribution, metabolism, and excretion studies of this GnRH receptor antagonist.

• 25-Hydroxycholesterol Rewires TAM Immunometabolism

  2026-08-21

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as a lysosome-centered immunometabolic checkpoint that activates AMPKα and reinforces STAT6-dependent ARG1 production in tumor-associated macrophages. The study connects oxysterol storage, mTORC1 signaling, macrophage suppression, and anti-PD-1 response, providing a framework for testing metabolic interventions in tumor immunity.

• SLC25A1, Senescence, and Cisplatin Resistance in HNSCC

  2026-08-20

  Li et al. identify SLC25A1 as a metabolic and epigenetic regulator of cisplatin resistance in head and neck squamous cell carcinoma, linking mitochondrial citrate transport to H3K27ac-dependent transcription and cellular senescence. The findings position SLC25A1 as a candidate biomarker and therapeutic target while emphasizing the need for multidimensional senescence validation in resistance studies.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-08-20

  Zhao and colleagues present a standardized whole-blood stimulation protocol that combines defined immune challenges with pharmacological modulation of cellular metabolism. The workflow preserves blood-based cellular interactions while enabling cytokine responses to be interpreted alongside glycolytic, anabolic, and catabolic perturbations, supporting more reproducible immunometabolism research.

• SFRP1, Wnt/β-Catenin, and Oral Fibrosis

  2026-08-19

  The reference study identifies reduced SFRP1 as a feature of arecoline-induced oral submucous fibrosis and links its loss to neutrophil infiltration, collagen accumulation, and canonical Wnt/β-catenin activation. By combining SFRP1 overexpression with pathway reactivation experiments, the authors provide mechanistic evidence that SFRP1 may limit oral fibrosis through coordinated immune and signaling effects.

• DeferoxamineB in Iron-Driven Cancer Biology

  2026-08-19

  DeferoxamineB offers translational researchers a controlled way to interrogate iron dependence, oxidative stress, apoptosis, and autophagy in cancer models. This thought-leadership perspective connects its use as an iron-chelation tool with emerging ferroptosis, cuproptosis, metabolic, and tumor-immunity research without treating distinct death pathways as interchangeable.

• circ_0042103/TAF15/NER Axis in Pulpitis

  2026-08-18

  The reference study identifies a circ_0042103/TAF15/NER regulatory axis that connects circular RNA activity with DNA damage and inflammation in pulpitis. Its combination of transcriptomic profiling, stem-cell models, and mechanistic RNA–protein assays provides a framework for studying how circRNAs influence repair capacity in inflamed dental pulp.

• PRINT: RNA-Mediated Insertion at Safe-Harbor Loci

  2026-08-18

  The reference study introduces PRINT, an RNA-only strategy that uses avian R2 retroelement proteins to insert transgenes at a multicopy human safe-harbor locus through target-primed reverse transcription. Its combination of site-directed integration, no donor DNA, and substantial insertion efficiency provides a mechanistic alternative to conventional CRISPR repair and viral delivery, while leaving important questions about locus scope, cargo size, cell-type transferability, and long-term genomic behavior.

• Acifran: A Structure-Informed Assay Guide

  2026-08-17

  Acifran is a receptor-active compound for dissecting HCAR2/GPR109A and HCAR3/GPR109B signaling in lipid metabolism research. This guide translates recent cryo-EM findings into practical decisions for pathway assays, compound handling, and interpretation.

• DMH1 Workflows for BMP and Organoid Research

  2026-08-17

  DMH1 is a selective ALK2 inhibitor for dissecting BMP-driven signaling, organoid behavior, and NSCLC phenotypes. This workflow-focused guide connects pathway-specific readouts with practical stock preparation, concentration scouting, migration assays, and organoid optimization while clearly separating established evidence from testable extensions.

• EZ Cap™ Human PTEN mRNA: Translational Cancer Strategy

  2026-08-16

  A mechanistic and translational roadmap for using EZ Cap™ Human PTEN mRNA to investigate PTEN restoration, PI3K/Akt signaling, mRNA delivery, and localized melanoma immunotherapy.

• U-73122 for PLC Signaling Workflows

  2026-08-15

  Build reproducible calcium-flux, chemotaxis, and breast-cancer invasion assays with U-73122, using concentration and timing controls that distinguish PLC dependence from general cytotoxicity. This practical guide connects phospholipase C inhibition to the QPRT–myosin light-chain findings while highlighting formulation, assay, and interpretation safeguards.

8283 records 1/553 page Next 12345 下5页 Last page